Wave Life SciencesWVE
About: WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Employees: 288
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
103% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 37
96% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 24
73% more call options, than puts
Call options by funds: $9.23M | Put options by funds: $5.33M
61% more capital invested
Capital invested by funds: $985M [Q3] → $1.59B (+$605M) [Q4]
33% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]
13% more funds holding
Funds holding: 160 [Q3] → 181 (+21) [Q4]
9.53% less ownership
Funds ownership: 93.82% [Q3] → 84.28% (-9.53%) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Andrew Fein 27% 1-year accuracy 95 / 352 met price target | 259%upside $22 | Buy Reiterated | 26 Mar 2025 |
Jefferies Roger Song 11% 1-year accuracy 2 / 18 met price target | 325%upside $26 | Buy Initiated | 25 Feb 2025 |
Financial journalist opinion
Based on 5 articles about WVE published over the past 30 days
